Graviton Bioscience Corporation
United States
unknown
unknown
Stage
About
Graviton Bioscience Corporation is developing selective ROCK2 inhibitors, including their lead asset GV101, for the treatment of fibrotic and autoimmune diseases such as Graft Versus Host Disease and Idiopathic Pulmonary Fibrosis.
Explore Graviton Bioscience Corporation's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.